Methods
We performed a MEDLINE search of the Englishlanguage literature, using combinations of the MESH headings "spinal stenosis" and "spondylolisthesis," in conjunction with any of the following subheadings, "rehabilitation," "surgery," and "therapy." We searched for publications between 1995 (the year X-STOP was introduced) and August 2008. Of the 1624 articles yielded by the search, we excluded laboratory studies, letters to the editor, editorials, reviews not containing original data, and case series duplicating previously published data. This left 108 publications, which we reviewed for outcome and cost statistics. All publications are considered Level I evidence (the 2007 and 2008 publications by Weinstein and colleagues 30, 31 ), Level II evidence (Thomé et al. 27 ), or Level III evidence (the remaining 105 publications).
The investigators used many different metrics for outcome, which limited our ability to compare the relative success of various management strategies. We adopted the SF-36 as a reasonable surrogate for utility, or HRQOL. The SF-36 is a 36-question multipurpose health survey. 29 Answers to the questions are used to score 8 scales, which in turn are aggregated into 2 summary measures, a physical and a mental component of HRQOL.
Responses have been normalized against population averages from 50 countries and various times to minimize scoring heterogeneity among different populations. The 2 summary measures total 100 for the population norms; lower scores are thought to correlate linearly with lower HRQOL. This permits us to conveniently use the aggregate SF-36 score/100 as a surrogate for utility. 16 Treatment groups were divided into conservative (nonsurgical) management, decompressive laminectomy, and interspinous placement of X-STOP. Each case series was reviewed for mean aggregate SF-36 scores of its patients before treatment and at 6, 12, and 24 months thereafter. Also collected were proportions of cases in which surgery was performed at one or multiple levels, and proportion of patients in whom additional surgical treatment was needed by 2 years of follow-up (2-year failure rates). Perioperative mortality rates were also sought (none were reported in any of the studies used).
Data from multiple case series were tested for heterogeneity and pooled meta-analytically. Standard errors of the prevalence values obtained from individual series were calculated using the normal approximation to the binomial distribution. 15 Pooled values for means and 95% CIs were obtained using the random-effects model of the metan function in Stata 9 (StataCorp).
Effectiveness of treatment was calculated, using the cumulative HRQOL over a 2-year time horizon. Pooled mean SF-36 scores were divided by 100 and multiplied by the time intervals to calculate QALYs, a generally accepted metric of health effect. 16 Because we anticipated that baseline HRQOL would differ among the 3 groups, we measured treatment effectiveness as percent increase (or decrease) in QALYs from baseline at the end of the 2-year treatment period. We considered direct health care costs from the perspective of society, and used as a proxy for these costs means and distributions obtained from 2008 Medicare national average reimbursements.
10,11 National levels of reimbursement have not yet been established for interspinous placement of X-STOP, which currently has a tracking code and is reimbursed on a state-by-state basis. We determined mean cost and distribution by sampling case numbers and reimbursements from the 16 states in which, at the time of writing, Medicare recorded reimbursement. All costs were expressed in 2008 US dollars. We assumed that laminectomies are all performed on inpatients, X-STOP involves only outpatient surgery, and all patients incur the same costs for nonsurgical care, such as medication, medical supplies, physical therapy, and other rehabilitation costs. Therefore, we did not include the latter in our calculations. Medicare payments for inpatient laminectomy are not altered by hospital length of stay, and so, this factor was not considered in the analysis. Indirect costs associated with illness and treatment, such as lost wages, were not included as they are beyond the scope of this study. All costs and QALYs were discounted at a 3% annual rate. 16 We created a cost-effectiveness model that reconstructed the course and outcomes encountered by a hypothetical patient receiving any of the 3 treatment strategies. Each treatment was either successful or would fail and be followed by additional surgery. For treatment failures, QALYs were reduced by 10% and costs were increased by the amount of the additional surgery compared with successes. The probabilities, scores, and costs calculated above determined the outcomes of each branch of the model, which is shown in Fig. 1 . Since many of the X-STOP treatment failures involved spinous process fracture, making reinsertion of X-STOP impossible, we assumed that surgery for treatment failure was always laminectomy for the same number of levels treated originally. Because costs for surgery to 2 spinal levels is considerably higher than for 1, we ran the model to calculate costs for treating the number of levels actually treated and then ran it 2 more times-once as if all operations had involved 1 level and once as if all operations had involved 2 levels.
In our primary analysis we evaluated the optimal management strategy for a patient with spinal stenosis at a 2-year time horizon. Secondary analyses were performed to compare patients requiring surgery at a single spinal level (2-year time horizon) and to compare patients requiring surgery at multiple levels (2-year time horizon); in addition, all 3 analyses were performed a second time using a 4-year time horizon. We calculated the number of QALYs gained over the 2 (or 4) years of treatment, expected cost, and cost per QALY. We performed sensitivity analysis for each parameter of the model within its 95% CI to determine its relative influence on outcomes and costs. The cost-effectiveness analysis followed standard principles. 16 Calculation of the cost-effectiveness used beta distributions for probabilities, normal distributions for utilities and costs, and a 2D Monte Carlo simulation 13 (expected value for 1000 simulated trials, each made up of 1000 microsimulations). If a particular strategy was found to be both more effective and less costly than the alternatives, it was said to dominate the other options, and we did not report a (negative) cost-effectiveness ratio. Analyses of the model employed TreeAge Pro 2008 (Tree Age Software, Inc.). The model was also run for 4-to 5-year follow-up data.
Results
Pooled prevalence and utility values used in the analyses are presented in Table 1 . The mean values are shown, along with the number of patients used in the determination and the 95% CIs of each meta-analytical mean. Table  2 illustrates the components of the cost determinations. Medicare coding and reimbursement for X-STOP is in transition at the time of this writing; the posted numbers represent the best figures available at the time of analysis.
One-way sensitivity analysis revealed that the variables that seemed to influence both relative cost and effectiveness of treatment were the cost and the utility of decompressive laminectomy. When varied between their 95% CIs, these 2 parameters exercised more weight on outcome than the other variables. Even at the extreme values, relative standings of the 3 management strategies remained the same. As is evident from Table 1 , X-STOP involved a much smaller proportion of multiple level surgeries than did laminectomy (20% vs 68%). Table 3 shows the relative costs and effectiveness of the 3 treatments, arranged from most effective (laminectomy) to least (conservative). Figure 2 illustrates the relationship among the 3 alternative therapies. This scatterplot represents 1000 virtual trials and shows the cost and effectiveness of each. As is evident, both laminectomy and X-STOP are more effective and more expensive than nonsurgical treatment, but overlap each other to a considerable degree. Table 3 also demonstrates quantitative comparisons. Since laminectomy is both more effective and less costly than X-STOP, it is said to dominate. Laminectomy is more effective than nonsurgical treatment but is also more expensive. This relationship is quantified by the incremental cost-effectiveness ratio (ICER), calculated by dividing the difference in cost between the 2 choices by the difference in effectiveness. This ratio represents the dollar cost of purchasing an additional QALY, in this case almost $60,000. Whether the choice of laminectomy over conservative treatment is cost-effective depends on a society's willingness to pay for it. Although $50,000 per QALY was once considered the limit of costeffectiveness, more recent studies suggest that a modern figure is near $200,000. 7 The acceptability curve allows one to visualize the relationship between willingness to pay and cost-effectiveness. 14 In Fig. 3 , the price society is willing to pay to improve quality of life by 1 QALY is plotted against cost-effectiveness. In the case of laminectomy, with willingness to pay assumed to be $50,000, it is more cost-effective than nonsurgical treatment in only slightly more than 40% of the cases in our virtual trial. However, if willingness to pay is increased to $200,000, it is more cost-effective nearly 90% of the time. This difference is significant (p < 0.05). The curve for X-STOP is parallel but somewhat less likely than laminectomy to be cost-effective.
The effects of 1-and 2-level surgery on costs and cost-effectiveness are shown in Table 4 . If only a single spinal level is involved, laminectomy is both more effective and more costly than X-STOP. If willingness to pay is only around $50,000, X-STOP is cost-effective compared with conservative management. However, at a willingness to pay above $100,000, laminectomy is more cost-effective than X-STOP. This relationship is illustrated in Fig.  4 , a 2-way sensitivity, or threshold analysis. In the case of 2-level stenosis, laminectomy dominates X-STOP and is more cost-effective than nonoperative care at a willingness to pay threshold below $60,000.
For follow-up beyond 24 months, the data are sparse and consequently uncertainty is greater. Only patients receiving nonoperative treatment (135 cases) and laminectomy (254 cases) are included. 5, 9, 12 The only published report on long-term follow-up of X-STOP insertion at the time of this writing 20 did not employ SF-36 scores. The mean 4-to 5-year SF-36 scores for conservative care and laminectomy are 92.9 (95% CI 92.3-93.5) and 91.3 (95% CI 89.7-92.8), respectively. Late treatment failure rates (after 2 years) are 0.7% and 0.8%, respectively. Inserting these values into a 4-year model resulted in the outputs shown in Table 5 . The cost-effectiveness of laminectomy is significant, even at the low willingness to pay threshold of $50,000/QALY.
Discussion
In the present study, clinical and cost data were used to perform a cost-effectiveness analysis of the common treatment strategies for patients with lumbar stenosis: conservative therapy, laminectomy, and X-STOP placement. Our primary analysis used a 2-year follow-up period and showed laminectomy to be the most cost-effective strategy, followed by X-STOP placement and then conservative therapy.
Given that many X-STOP procedures in our pooled data were performed for single-level disease, a secondary analysis was completed stratifying 1-and 2-level surgeries. For single-level surgery, laminectomy was more effective, but X-STOP was less costly. This cost difference was largely due to the fact that laminectomy was performed as an inpatient procedure, whereas X-STOP was performed in an ambulatory setting. For 2-level surgery, laminectomy was both more effective and less costly than X-STOP. If society were purely focused on clinical effectiveness, laminectomy clearly would dominate in all cases. If cost is considered, a balance must be struck for single-level procedures. While the cost per QALY added by both laminectomy and X-STOP is within accepted modern norms, the incremental cost per QALY is about $50,000 more for single-level laminectomy than for X-STOP under our study parameters. Although there is not enough long-term outcome data on X-STOP to include it in a meaningful analysis, we were able to show that the cost-effectiveness of laminectomy persisted and its domination increased compared with conservative therapy when a follow-up of 4 years was used.
Since the X-STOP was introduced, numerous case series have been published to illustrate its safety and effectiveness. 8, 22, 23, 26 Several studies have been completed that compare the X-STOP procedure with other treatment strategies. 3, 17, 33, 34 These studies have been criticized as they compare X-STOP with conservative therapy rather than with surgical decompression. 6 To date, a well-designed randomized trial of X-STOP and laminectomy has not been published, making comparisons of these treatments a complicated task for practitioners. There has been one study published examining the cost of X-STOP versus laminectomy. Kondrashov et al. 21 found X-STOP to be significantly more cost-effective than laminectomy. However, that study used the cost perspective of the hospital rather than that of society and thus failed to follow stan- dard cost-effectiveness principles. In addition, charges were used instead of cost data, and no incremental costeffectiveness ratios were calculated. Lastly, the senior author on the study was one of the inventors of the X-STOP device and has financial ties to the manufacturer. Our own study is limited by the many assumptions required for construction of a mathematical model and is, at best, an approximation of the results of a clinical trial. Wherever possible, we have made assumptions that were neutral or that favored X-STOP and nonoperative treatment over laminectomy. For example, multilevel laminectomy series often include surgeries of 3 or more levels. We also omitted the added costs of plain radiographs after X-STOP placement, as the number of studies performed varies with the center involved and the clinical course of each patient. We combined the various types of decompressive procedures under the laminectomy rubric; we also combined spondylolisthesis with isolated lumbar stenosis. We chose to treat all laminectomies as inpatient procedures (favoring X-STOP) since the cost-savings benefit of being able to perform all X-STOP procedures in the outpatient setting has been mentioned as a significant differentiator between X-STOP and laminectomy. Lastly, we calculated that treatment failures would be treated by laminectomy with its associated costs, while it may be that some failures would require more extensive revision surgery, including fusion, and could be more costly. We chose the SF-36 as our measure of HRQOL, a wellestablished standard but one that cannot easily be compared with other scales. 4, 28, 32 We were therefore unable to compare results to case series using other measures of HRQOL. Thus, long-term follow-up comparisons with X-STOP cannot be made, since the reports of follow-up beyond 2 years do not report SF-36 scores. 21, 35 We must also note that not all patients started at the same point regarding HRQOL. Laminectomy patients had the lowest pretreatment SF-36 scores, and patients treated conservatively the highest. Our calculations dealt only with changes in scores over the course of treatment, thus minimizing this difference.
Perhaps the greatest shortcoming of our study is the inability to account for differences in patient selection in published series. Some patients treated in case series reporting laminectomy results would not have been con- Fig. 4 . Threshold analysis for 1-level operation. A 2-way sensitivity analysis (number of QALYs added by a successful laminectomy are plotted against its cost). The dark gray area represents values where X-STOP would be more cost-effective than laminectomy at a willingness-to-pay of $100,000 per QALY gained, light gray at $50,000. Actual results (shown above with 95% CIs) suggest that laminectomy is the more cost-effective strategy at a willingness to pay of $100,000 per QALY gained, whereas X-STOP is more cost-effective at a willingness to pay of $50,000 per QALY gained. sidered for X-STOP insertion and vice versa. The ideal X-STOP patient has limited LSS, with a modest reduction in foraminal area. In contrast, severe central canal stenosis has been found to be a positive predictor of success with laminectomy 1 and LSS most often involves multiple spinal levels. 2, 18, 19, 24, 31 
Conclusions
With the recent addition of a large and well-designed randomized clinical trial, the literature favoring surgical decompression over conservative therapy for lumbar stenosis appears strong. 31 Until a similar trial has been completed comparing X-STOP with laminectomy, no claims of superior outcomes or cost-effectiveness for X-STOP can be made. In fact, our analysis suggests laminectomy to be a more cost-effective surgical strategy than X-STOP in this patient population.
